|3 Months Ended|
Mar. 31, 2022
|Subsequent Events [Abstract]|
Note 15 – Subsequent Event
On April 8, 2022, the Company entered into an exclusive research collaboration with BioNTech SE to evaluate the combination of mRNA formats utilizing the Company’s proprietary LNC platform technology. Under the terms of the agreement, the Company will receive an exclusivity fee in the amount of $2.75 million, and BioNTech SE will fund certain of the Company’s research expenses related to the collaboration. The parties have also commenced discussions on a potential license agreement for the Company’s LNC platform technology.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef